Breast cancer study: does adding trastuzumab to Pre-Surgery chemo improve outcomes?

NCT ID NCT01750073

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This phase II trial studied 92 women with early-stage breast cancer to see how well chemotherapy (paclitaxel and cyclophosphamide) with or without trastuzumab works before surgery. The main goals were to check side effects and see if the tumor disappears completely by the time of surgery. The study included patients with different types of breast cancer, including HER2-positive and HER2-negative.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
paclitaxel, cyclophosphamide, and trastuzumab
What this could lead to
If successful, this could show that adding trastuzumab to chemotherapy before surgery helps shrink tumors more effectively in HER2-positive breast cancer patients.
What could go wrong
This is a small, completed phase II trial, so results are preliminary. The approach may not work for all breast cancer types, and chemotherapy carries risks like infection and heart damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESTROGEN RECEPTOR NEGATIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHI Health Saint Francis

    Grand Island, Nebraska, 68803, United States

  • Nebraska Medicine-Bellevue

    Bellevue, Nebraska, 68123, United States

  • Nebraska Medicine-Village Pointe Cancer Center

    Omaha, Nebraska, 68118, United States

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.